Mitapivat
Sign in to save this workspacePrimary targets: PK · FDA status: FDA Approved
Selectivity scorecard
KISS
100.00
Gini
0.625
CATDS
0.028
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Mitapivat. Strongest target: PDGFRA at 53.3% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | PDGFRA | 53.3% | 46.7% |
| 2 | C_KIT | 48.1% | 51.9% |
| 3 | AURORA_A | 30.6% | 69.4% |
| 4 | PDGFRB | 26.1% | 73.9% |
| 5 | LIMK1 | 25.3% | 74.7% |
| 6 | PDK3_PDHK3 | 23.8% | 76.3% |
| 7 | PKD2_PRKD2 | 21.2% | 78.8% |
| 8 | ASK1_MAP3K5 | 20.9% | 79.1% |
| 9 | CDK4_CYCLIN_D3 | 20.2% | 79.8% |
| 10 | DDR1 | 19.1% | 80.9% |
| 11 | DAPK2 | 18.8% | 81.2% |
| 12 | MELK | 18.1% | 81.9% |
| 13 | TRKB | 18.0% | 82.0% |
| 14 | CDK9_CYCLIN_T2 | 17.9% | 82.1% |
| 15 | VRK1 | 17.5% | 82.5% |
| 16 | LCK | 17.4% | 82.6% |
| 17 | RIPK2 | 16.8% | 83.2% |
| 18 | AURORA_B | 16.7% | 83.3% |
| 19 | MEKK6 | 16.2% | 83.8% |
| 20 | MST2_STK3 | 15.3% | 84.7% |
Selectivity landscape
Where Mitapivat sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Mitapivat.
Atlas insights for Mitapivat
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.845 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.833 |
| SRR23303752 | — | 0.825 |
| aMVAC.P_005_TURBT_S223 | — | 0.819 |
| SRR12202498 | — | 0.814 |
Annotations
Sign in to read and post annotations.
Loading…